JLP-2008 / Jeil - LARVOL DELTA

JLP-2008 Fixed-Dose Combination Tablet Demonstrates Bioequivalence and Comparable Safety to Separate Dapagliflozin + Pioglitazone in Healthy Participants. (PubMed, Eur J Drug Metab Pharmacokinet) - P1 | "JLP-2008 delivers systemic exposures to dapagliflozin and pioglitazone equivalent to those from co-administration of individual tablet and is well tolerated. FDC may provide a more convenient treatment option for patients with type 2 diabetes mellitus (T2DM), and its use was supported by comparable pharmacokinetic and safety profiles."

Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008 (clinicaltrials.gov) - P1 | N=48 | Completed | Sponsor: Jeil Pharmaceutical Co., Ltd.

New P1 trial